Efficiency of amifostine as a protection against doxorubicin toxicity in rats during a 12-day treatment

Anticancer Research

Volumn 23, Issue 1 A, 2003, Pages 405-409

  Nazeyrollas, P ^a,b   Frances, C ^a   Prevost, A ^c   Costa, B ^c   Lorenzato, M ^b   Kantelip, Jp ^d   Elaerts, J ^b   Millart, H ^a  

^a UNIVERSITÉ DE REIMS CHAMPAGNE ARDENNE   (France)

^b REIMS UNIVERSITY HOSPITAL   (France)

^c INSTITUT JEAN GODINOT   (France)

^d Lab Physiologie et Pharmacologie   (France)

Author keywords

Amifostine; Cardioprotection; Cardiotoxicity; Doxorubicin; Isolated rat heart

Indexed keywords

AMIFOSTINE; DOXORUBICIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CARDIOTOXICITY; CELL PROTECTION; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG TOLERANCE; HEART CONTRACTION; HEART FUNCTION; HEART LEFT VENTRICLE PRESSURE; INJECTION; ISOLATED HEART; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; WEIGHT REDUCTION;

AMIFOSTINE; ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; BODY WEIGHT; DOXORUBICIN; DRUG INTERACTIONS; HEART; MALE; MYOCARDIAL CONTRACTION; RATS; RATS, WISTAR; VENTRICULAR FUNCTION, LEFT;

EID: 0037233680     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Kemp G, Rose P, Lurain J et al.: Amifostine pretreatment for protection against cyclophosphamide-induced and cisplatin-induced toxicities: results of a randomized control trial in patients with advanced ovarian cancer. J Clin Oncol 14: 2101-2112, 1996.
2. Buntzel J, Kuttner K, Frohlich D and Glatzel M: Selective cytoprotection with amifostine in concurrent radiochemotherapy for head and neck cancer [see comments]. Ann Oncol 9: 505-509, 1998.
3. Calabro-Jones PM, Aguilera JA, Ward JF, Smoluk GD and Fahey RC: Uptake of WR-2721 derivatives by cells in culture: identification of the transported form of the drug. Cancer Res 48: 3634-3640, 1988.
4. Smoluk GD, Fahey RC, Calabro-Jones PM, Aguilera JA and Ward JF: Radioprotection of cells in culture by WR-2721 and derivatives: form of the drug responsible for protection. Cancer Res 48: 3641-3647, 1988.
5. Capizzi R: Amifostine: the preclinical basis for broad-spectrum selective cytoprotection of normal tissues from cytotoxic therapies. Semin Oncol 23: 2-17, 1996.
6. Nazeyrollas P, Prevost A, Baccard N, Manot L, Devillier P and Millart H: Effects of amifostine on perfused isolated rat heart and on acute doxorubicin-induced cardiotoxicity. Cancer Chemother Pharmacol 43: 227-232, 1999.
7. Dorr RT, Lagel K and McLean S: Cardioprotection of rat heart myocytes with amifostine (Ethyol) and its free thiol, WR-1065, in vitro. Eur J Cancer 32A: Suppl 4: S21-5, 1996.
8. Treskes M, Holwerda U, Klein I, Pinedo HM and van der Viigh WJ: The chemical reactivity of the modulating agent WR2721 (ethiofos) and its main metabolites with the antitumor agents cisplatin and carboplatin. Biochemical Pharmacology 42: 2125-2130, 1991.
9. Ramakrishnan N and Catraves GN: N-(2-mercaptoethyl)-1,3 propanediamine (WR-1065) protects thymocytes from programmed cell death. J Immunol 148: 817, 1992.
10. Pouna P, Bonoron-Adele S, Gouverneur G, Tariosse L, Besse P and Robert J: Development of the model of rat isolated perfused heart for the evaluation of anthracycline cardiotoxicity and its circumvention. Br J Pharmacol 117: 1593-1599, 1996.
11. Herman EH, Zhang J, Chadwick DP and Ferrans VJ: Comparison of the protective effects of amifostine and dexrazoxane against the toxicity of doxorubicin in spontaneously hypertensive rats. Cancer Chemother Pharmacol 45: 329-334, 2000.
12. Yuhas JM: Biological factors affecting the radioprotective efficiency of S-2-[2-aminopropylamino] ethylphosphorothioic acid (WR-2721). LD50(3)) doses. Radiat Res 44: 621-628, 1970.
13. van der Wilt CL, van Laar JA, Gyergyay F, Smid K and Peters GJ: Biochemical modification of the toxicity and the anti-tumour effect of 5-fluorouracil and cis-platinum by WR-2721 in mice. Eur J Cancer 28A: 2017-2024, 1992.
14. Paine GD, Taylor CW, Lopez MH, Johnson CS and Capizzi RL: Effects of amifostine and paclitaxel on growth of human ovarian carcinoma xenografts in the severe combined immune-deficient mouse: preliminary results. Semin Oncol 23: 35-39, 1996.
15. Raza A, Qawi H, Lisak L et al.: Patients with myelodysplastic syndromes benefit from palliative therapy with amifostine, pentoxifylline, and ciprofloxacin with or without dexamethasone. Blood 95: 1580-1587, 2000.
16. Adamson PC, Balis FM, Belasco JE et al.: A phase I trial of amifostine (WR-2721) and melphalan in children with refractory cancer. Cancer Res 55: 4069-4072, 1995.
17. Mettler CE, Young DM and Ward JM: Adriamycin-induced cardiotoxicity (cardiomyopathy and congestive heart failure) in rats. Cancer Res 37: 2705-2713, 1977.
18. Cottin Y, Ribuot C, Maupoil V et al.: Early incidence of adriamycin treatment on cardiac parameters in the rat. Can J Physiol Pharmacol 72: 140-145, 1994.
19. Pissarek M, Janichen F, Blasig IE et al.: Cardioprotective potency of the radical scavenger S-2-(3 aminopropylamino) ethylphosphorothioic acid in the post-ischaemic rat heart. Mol Cell Biochem 145: 121-129, 1995.
20. Dorr RT, Shipp NG and Lee KM: Comparison of cytotoxicity in heart cells and tumor cells exposed to DNA intercalating agents in vitro. Anticancer Drugs 2: 27-33, 1991.
21. Doroshow JH: Effect of anthracycline antibiotics on oxygen radical formation in rat heart. Cancer Res 43: 460-472, 1983.
22. Gustafson DL, Swanson JD and Pritsos CA: Modulation of glutathione and glutathione dependent antioxidant enzymes in mouse heart following doxorubicin therapy. Free Radic Res Commun 19: 111-120, 1993.
23. Myers C: The role of iron in doxorubicin-induced cardiomyopathy. Semin Oncol 25: 10-14, 1998.
24. Marzatico F, Porta C, Moroni M et al.: In vitro antioxidant properties of amifostine (WR-2721, Ethyol). Cancer Chemother Pharmacol 45: 172-176, 2000.
25. Arai M, Tomaru K, Takizawa T et al.: Sarcoplasmic reticulum genes are selectively down-regulated in cardiomyopathy produced by doxorubicin in rabbits. J Molec Cell Cardiol 30: 243-254, 1998.
26. Ravingerova T, Slezak J, Tribulova N, Dzurba A, Uhrik B and Ziegelhoffer A: Free oxygen radicals contribute to high incidence of reperfusion-induced arrhythmias in isolated rat heart. Life Sci 65: 1927-1930, 1999.
27. Harris RN and Doroshow JH: Effect of doxorubicin-enhanced hydrogen peroxide and hydroxyl radical formation on calcium sequestration by cardiac sarcoplasmic reticulum. Biochem Biophys Res Commun 130: 739-745, 1985.
28. Kim DH, Landry ABd, Lee YS and Katz AM: Doxorubicin-induced calcium release from cardiac sarcoplasmic reticulum vesicles. J Molec Cell Cardiol 21: 433-436, 1989.
29. Boucek RJJ, Buck SH, Scott F, Oquist NL, Fleischer S and Olson RD: Anthracycline-induced tension in permeabilized cardiac fibers: evidence for the activation of the calcium release channel of sarcoplasmic reticulum. J Molec Cell Cardiol 25: 249-259, 1993.
30. Arai M, Yoguchi A, Takizawa T et al.: Mechanism of doxorubicin-induced inhibition of sarcoplasmic reticulum Ca2+-ATPase gene transcription. Circulation Res 86: 8-14, 2000.
31. Boucek RJJ, Miracle A, Anderson M, Engelmann R, Atkinson J and Dodd D: Persistent effects of doxorubicin on cardiac gene expression. J Molec Cell Cardiol 31: 1435-1446, 1999.